Summit Therapeutics Inc.
SMMT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001599298
No open-market purchases or sales by Summit Therapeutics Inc. insiders were filed in the last 90 days; 242 institutions reported holding it in 13F filings for Q2 2026, worth $1.98B in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Summit Therapeutics Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 48 | 1 | 41 | −6 |
| Shares | 11.0M | 4.29K | 8.46M | −2.54M (−23.1%) |
| Value | $27.4M | $11.0K | $8.46M | −$18.9M (−69.1%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (13)
Institutions that held Summit Therapeutics Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 457,468 | $457.0K | 0.00% |
| Ergoteles LLC | 100,722 | $101.0K | 0.00% |
| Citadel Advisors LLC | 56,743 | $57.0K | 0.00% |
| Renaissance Technologies LLC | 49,118 | $49.0K | 0.00% |
| Susquehanna International Group, LLP | 23,637 | $24.0K | 0.00% |
| Qube Research & Technologies Ltd | 18,811 | $19.0K | 0.00% |
| Cowen and Company, LLC | 18,049 | $18.0K | 0.00% |
| Bender Robert & Associates | 14,059 | $14.0K | 0.01% |
| Y-Intercept (Hong Kong) Ltd | 10,355 | $10.0K | 0.00% |
| Evoke Wealth, LLC | 5,000 | $5.00K | 0.00% |
| Harbour Investments, Inc. | 1,300 | $1.00K | 0.00% |
| Credit Suisse AG | 14 | $0 | 0.00% |
| Simplex Trading, LLC | 63 | $0 | 0.00% |
Sold out (19)
Institutions that held Summit Therapeutics Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Baillie Gifford & Co | 436,512 | $1.07M |
| State Street Corp | 313,401 | $768.0K |
| Northern Trust Corp | 175,682 | $431.0K |
| Nuveen Asset Management, LLC | 54,748 | $178.0K |
| Charles Schwab Investment Management Inc | 61,313 | $151.0K |
| Bank of New York Mellon Corp | 49,763 | $122.0K |
| Allspring Global Investments Holdings, LLC | 33,915 | $83.0K |
| Rhumbline Advisers | 15,115 | $37.0K |
| ProShare Advisors LLC | 15,054 | $37.0K |
| Deutsche Bank AG | 14,310 | $35.0K |
| American International Group, Inc. | 13,087 | $32.0K |
| Invesco Ltd. | 11,273 | $28.0K |
| California State Teachers Retirement System | 11,186 | $27.0K |
| Voya Investment Management LLC | 10,629 | $26.0K |
| Amalgamated Bank | 4,291 | $11.0K |
| Legal & General Group Plc | 2,770 | $7.00K |
| Royal Bank of Canada | 1,620 | $4.00K |
| Ameritas Investment Partners, Inc. | 1,762 | $4.00K |
| FMR LLC | 729 | $2.00K |
Not filed for Q2 2022 yet (1)
Institutions that held Summit Therapeutics Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Amalgamated Financial Corp. | 4,291 | $11.0K |